source
- FDA reverses earlier stance, grants uniQure accelerated approval pathway for Huntington's gene therapyOn June 17, 2026, the U.S. Food and Drug Administration issued a second reversal, allowing biotech company uniQure to pursue an accelerated approval pathway for its gene therapy targeting Huntingto…
- Triveni Bio secures $65M Series C as second eczema candidate enters clinical trialsTriveni Bio announced a $65 million Series C financing round aimed at supporting its ongoing development programs. The round was co‑led by Ascenta Capital and Janus Henderson Investors, with parti…